An interview with Dr Chhatwal The phase 3 plan, which is currently open for enrollment, will include more than 2,000 patients with HCV genotype 1, with trial sites in 29 countries. The DAAs in the studies consist of ABT-450/r , ABT-267 and ABT-333 . Treatment duration will be 12 weeks in non-cirrhotic sufferers, and 12 or 24 weeks in cirrhotic patients. All individuals will be adopted for 48 weeks post-treatment. Co-formulated tablets of ABT-450/r and ABT-267 will be utilized in the phase 3 trials.APP shall market Oxaliplatin Injection in 5 mg/mL single dose vials, available in 10 mL and 20 mL vial sizes. APP’s Oxaliplatin Injection is bar-coded, latex-free and preservative-free. ‘This approval enables APP to provide its customers a choice between the lyophilized item that APP currently marketplaces and a more convenient, ready to use liquid type,’ said John Ducker, President and Chief Executive Officer of APP Pharmaceuticals. ‘Adding Oxaliplatin Injection to your product offerings additional expands APP’s growing Oncology portfolio.’.. Accurate way for interpretation of heart pictures developed VTT – Technical Research Center of Finland has developed an internationally significant way for interpreting MRI images of the center.